WHO Classification of Tumours: Thoracic Tumours. 5th ed. Lyon, France: International Agency for Research on Cancer. 2021.
Yatabe Y, Dacic S, Borczuk AC, Warth A, Russell PA, Lantuejoul S, et al. Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. J Thorac Oncol. 2019 Mar 1;14(3):377–407.
DOI: 10.1016/j.jtho.2018.12.005
NCCN Guidelines 2023. Available from: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1461
Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023 Apr 1;34(4):339–57.
DOI: 10.1016/j.annonc.2022.12.009
Devereaux KA, Souers RJ, Graham RP, Portier BP, Surrey LF, Yemelyanova A, et al. Neoplastic Cellularity Assessment in Molecular Testing A Multi-institutional Practice Survey and Performance Challenge Identifies a Need for Standardization. Arch Pathol Lab Med. 2022 Sep 1;146(9):1062–71.
DOI: 10.5858/arpa.2021-0166-CP
Aggarwal C, Marmarelis ME, Hwang WT, Scholes DG, McWilliams TL, Singh AP, et al. Association Between Availability of Molecular Genotyping Results and Overall Survival in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer. JCO Precis Oncol. 2023 Jul;7:e2300191.
DOI: 10.1200/PO.23.00191
Tan AC, Tan DSW. Targeted Therapies for Lung Cancer Patients with Oncogenic Driver Molecular Alterations. J Clin Oncol. 2022 Feb 20;40(6):611–25.
DOI: 10.1200/JCO.21.01626
Mateo J, Steuten L, Aftimos P, André F, Davies M, Garralda E, et al. Delivering precision oncology to patients with cancer. Nat Med. 2022 Apr 1;28(4):658–65.
DOI: 10.1038/s41591-022-01717-2
Li M, Mok K, Mok T. Developments in targeted therapy & immunotherapy—how non-small cell lung cancer management will change in the next decade: a narrative review. Ann Transl Med. 2023 Aug;11(10):358–358.
DOI: 10.21037/atm-22-4444
Buttner R, Gosney JR, Skov BG, Adam J, Motoi N, Bloom KJ, et al. Programmed death-ligand 1 immunohistochemistry testing: A review of analytical assays and clinical implementation in non-small-cell lung cancer. J Clin Oncol. 2017 Dec 1;35(34):3867–76.
DOI: 10.1200/JCO.2017.74.7642
Lantuejoul S, Sound-Tsao M, Cooper WA, Girard N, Hirsch FR, Roden AC, et al. PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee. J Thorac Oncol. 2020 Apr 1;15(4):499–519.
DOI: 10.1016/j.jtho.2019.12.107
Conde E, Angulo B, Izquierdo E, Muñoz L, Suárez-Gauthier A, Plaza C, et al. The ALK translocation in advanced non-small-cell lung carcinomas: Preapproval testing experience at a single cancer centre. Histopathology. 2013 Mar;62(4):609–16.
DOI: 10.1111/his.12037
Conde E, Suárez-Gauthier A, Benito A, Garrido P, García-Campelo R, Biscuola M, et al. Accurate identification of ALK positive lung carcinoma patients: Novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry. PLoS One. 2014 Sep 23;9(9):e107200.
DOI: 10.1371/journal.pone.0107200
Conde E, Hernandez S, Prieto M, Martinez R, Lopez-Rios F. Profile of Ventana ALK (D5F3) companion diagnostic assay for non-small-cell lung carcinomas. Expert Rev Mol Diagn. 2016 Jun 2;16(6):707–13.
DOI: 10.1586/14737159.2016.1172963
Hernandez S, Conde E, Alonso M, Illarramendi A, Bote de Cabo H, Zugazagoitia J, et al. A narrative review of methods for the identification of ALK fusions in patients with non-small cell lung carcinoma. Transl Lung Cancer Res. 2023 Jul 31;12(7):1549–62.
DOI: 10.21037/tlcr-22-855
Sholl LM, Cooper WA, Kerr KM, Tan DSW, Tsao MS, Yang J. IASLC Atlas of Molecular Testing for Targeted Therapy in Lung Cancer 2023. Available from: https://www.iaslc.org/iaslc-atlas-molecular-testing-targeted-therapy-lung-cancer
Conde E, Hernandez S, Martinez R, Angulo B, De Castro J, Collazo-Lorduy A, et al. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study. J Thorac Oncol. 2019 Dec 1;14(12):2120–32.
DOI: 10.1016/j.jtho.2019.07.005
Marchiò C, Scaltriti M, Ladanyi M, Iafrate AJ, Bibeau F, Dietel M, et al. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Ann Oncol. 2019 Sep 1;30(9):1417–27.
DOI: 10.1093/annonc/mdz204
Conde E, Hernandez S, Sanchez E, Regojo RM, Camacho C, Alonso M, et al. Pan-TRK immunohistochemistry an example-based practical approach to efficiently identify patients with NTRK fusion cancer. Arch Pathol Lab Med. 2021 Aug 1;145(8):1031–40.
DOI: 10.5858/arpa.2020-0400-RA
Hernandez S, Conde E, Molero A, Suarez-Gauthier A, Martinez R, Alonso M, et al. Efficient Identification of Patients With NTRK Fusions Using a Supervised Tumor-Agnostic Approach. Arch Pathol Lab Med [Internet]. 2023 Jun 1 [cited 2023 Oct 13]; Available from:
DOI: 10.5858/arpa.2022-0443-OA
Conde E, Hernandez S, Alonso M, Lopez-Rios F. Pan-TRK immunohistochemistry to optimize the detection of NTRK fusions: removing the hay when looking for the needle. Mod Pathol [Internet]. 2023 Sep 25 [cited 2023 Oct 14];100346. Available from: https://pubmed.ncbi.nlm.nih.gov/37757968/
DOI: 10.1016/j.modpat.2023.100346
Rolfo C, Russo A. Exploiting the Full Potential of Novel Agents Targeting EGFR Exon 20 Insertions in Advanced NSCLC: Next-Generation Sequencing Outperforms Polymerase Chain Reaction–Based Testing. J Thorac Oncol. 2023 Jun 1;18(6):674–7.
DOI: 10.1016/j.jtho.2023.02.020
Lim TKH, Skoulidis F, Kerr KM, Ahn MJ, Kapp JR, Soares FA, et al. KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing. Lung Cancer. 2023 Oct;184:107293.
DOI: 10.1016/j.lungcan.2023.107293
Solomon JP, Yang SR, Choudhury NJ, Ptashkin RN, Eslamdoost N, Falcon CJ, et al. Bioinformatically Expanded Next-Generation Sequencing Analysis Optimizes Identification of Therapeutically Relevant MET Copy Number Alterations in >50,000 Tumors. Clin Cancer Res. 2022 Nov 1;28(21):4649–59.
DOI: 10.1158/1078-0432.CCR-22-1321
Eyerer FIR, Bradshaw G, Vasalos P, Laser JS, Chang CC, Kim AS, et al. Getting Your Laboratory on Track With Neurotrophic Receptor Tyrosine Kinase. Arch Pathol Lab Med. 2023 Aug 1;147(8):872–84.
DOI: 10.5858/arpa.2022-0042-CP
Rolfo C, Mack P, Scagliotti G V., Aggarwal C, Arcila ME, Barlesi F, et al. Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. J Thorac Oncol. 2021 Oct 1;16(10):1647–62.
DOI: 10.1016/j.jtho.2021.06.017
Krebs MG, Malapelle U, André F, Paz-Ares L, Schuler M, Thomas DM, et al. Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients with Cancer: A Narrative Review. JAMA Oncol. 2022 Dec 15;8(12):1830–9.
DOI: 10.1001/jamaoncol.2022.4457
Pascual J, Attard G, Bidard FC, Curigliano G, De Mattos-Arruda L, Diehn M, et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2022 Aug 1;33(8):750–68.
DOI: 10.1016/j.annonc.2022.05.520
Lockwood CM, Borsu L, Cankovic M, Earle JSL, Gocke CD, Hameed M, et al. Recommendations for Cell-free DNA Assay Validations: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists. J Mol Diagn. 2023;S1525-1578(23)00219-2.
DOI: 10.1016/j.jmoldx.2023.09.004
Hofman P, Berezowska S, Kazdal D, Mograbi B, Ilié M, Stenzinger A, et al. Current challenges and practical aspects of molecular pathology for non-small cell lung cancers. Virchows Arch. 2023 Oct 6; Available from: https://pubmed.ncbi.nlm.nih.gov/37801103/
DOI: 10.1007/s00428-023-03651-1
Tsao MiS, Hirsch FR, Yatabe Y. The IASLC Atlas of ALK and ROS1 Testing in Lung Cancer 2017. Available from: https://www.iaslc.org/research-education/publications-resources-guidelines/iaslc-atlas-alk-and-ros1-testing-lung-cancer
Mok TS, Carbone DP, Hirsh FR. The IASLC Atlas of EGFR Testing in Lun Cancer 2017. Available from: https://www.iaslc.org/research-education/publications-resources-guidelines/iaslc-atlas-egfr-testing-lung-cancer-guidebook
Hirsch FR. The IASLC Atlas of PD-L1 Immunohistochemistry ( IHC ) Testing in Lung Cancer 2017. Available from: https://www.iaslc.org/research-education/publications-resources-guidelines/iaslc-atlas-pd-l1-testing-lung-cancer
Belli C, Penault-Llorca F, Ladanyi M, Normanno N, Scoazec JY, Lacroix L, et al. ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research. Ann Oncol. 2021 Mar 1;32(3):337–50.
DOI: 10.1016/j.annonc.2020.11.021
Yang SR, Aypar U, Rosen EY, Mata DA, Benayed R, Mullaney K, et al. A performance comparison of commonly used assays to detect RET fusions. Clin Cancer Res. 2021 Mar 1;27(5):1316–28.
DOI: 10.1158/1078-0432.CCR-20-3208
Ren S, Wang J, Ying J, Mitsudomi T, Lee DH, Wang Z, et al. Consensus for HER2 alterations testing in non-small-cell lung cancer. ESMO open. 2022 Feb 1;7(3):100482.
DOI: 10.1016/j.esmoop.2022.100482
Mazieres J, Vioix H, Pfeiffer BM, Campden RI, Chen Z, Heeg B, et al. MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes. Clin Lung Cancer. 2023 Sep 1;24(6):483–97.
DOI: 10.1016/j.cllc.2023.06.008
Lim SM, Lee JB, Oya Y, Nutzinger J, Soo R. Path less Traveled: Targeting Rare Driver Oncogenes in Non-Small-Cell Lung Cancer. JCO Oncol Pr. 2023 Sep 21;OP2300273.
DOI: 10.1200/OP.23.00273
Mino-Kenudson M, Schalper K, Cooper W, Dacic S, Hirsch FR, Jain D, et al. Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee. J Thorac Oncol. 2022 Dec 1;17(12):1335–54.
DOI: 10.1016/j.jtho.2022.09.109
Hernandez S, Conde E, Alonso M, Veras M, Illarramendi A, Curto D, et al. 35th European Congress of Pathology. Virchows Arch. 2023 Sep 2;483(1):341 (Abstract E-PS-21-017).
DOI: 10.1007/s00428-023-03602-w
Número de descargas:
6228
Número de visitas:
690
Citas:
0
